论文信息 - Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study - 字舞流文

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study

J. Desai | E. Van Cutsem | J. Schellens | J. Tabernero | A. Grothey | R. Yaeger | M. Fakih | S. Kopetz | F. Ciardiello | A. Gollerkeri | C. Montagut | M. Peeters | H. Wasan | K. Maharry | T. Yoshino | V. Sandor | P. Cuyle | E. Élez | J. Christy-Bittel | S. Huijberts